Odalasvir

Odalasvir
Legal status

Legal status	Investigational New Drug
Identifiers
IUPAC name Dimethyl N,N'-(1,4(1,4)-dibenzenacyclohexaphane- 1²,4²-diylbis{1H-benzimidazole-5,2-diyl[(2S,3aS,7aS)- octahydro-1H-indole-2,1-diyl][(2S)-3-methyl-1-oxobutan- 1,2-diyl]})biscarbamate
CAS Number	1458063-52-9
PubChem (CID)	71474517
ChemSpider	34500837
UNII	OVR52K7BDW^Y
Chemical and physical data
Formula	C₆₀H₇₂N₈O₆
Molar mass	1001.26368 g/mol
3D model (Jmol)	Interactive image
SMILES CC(C)[C@@H](C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C3=NC4=C(N3)C=C(C=C4)C5=C6CCC7=CC(=C(CCC(=C5)C=C6)C=C7)C8=CC9=C(C=C8)N=C(N9)[C@@H]1C[C@@H]2CCCC[C@@H]2N1C(=O)[C@H](C(C)C)NC(=O)OC)NC(=O)OC
InChI InChI=1S/C60H72N8O6/c1-33(2)53(65-59(71)73-5)57(69)67-49-13-9-7-11-41(49)31-51(67)55-61-45-25-23-39(29-47(45)63-55)43-27-35-15-19-37(43)21-17-36-16-20-38(22-18-35)44(28-36)40-24-26-46-48(30-40)64-56(62-46)52-32-42-12-8-10-14-50(42)68(52)58(70)54(34(3)4)66-60(72)74-6/h15-16,19-20,23-30,33-34,41-42,49-54H,7-14,17-18,21-22,31-32H2,1-6H3,(H,61,63)(H,62,64)(H,65,71)(H,66,72)/t41-,42-,49-,50-,51-,52-,53-,54-/m0/s1 Key:LSYBRGMTRKJATA-IVEWBXRVSA-N

Odalasvir (INN,^[1] previously known as ACH-3102)^[2]^[3] is an investigational new drug in development for the treatment of hepatitis C.^[4] It is an NS5A inhibitor.^[5] The NS5A protein serves multiple functions at various stages of the viral life cycle, including viral replication. NS5A also plays a role in the development of interferon-resistance, a common cause of treatment failure.^[6]^[7]^[8]

References

↑ "International Nonproprietary Names for Pharmaceutical Substances (INN). RECOMMENDED International Nonproprietary Names: List 73" (PDF). who.int. World Health Organization. p. 38. Retrieved 5 December 2015.
↑ "Achillion Has Discovered and Developed a Comprehensive Portfolio of Antivirals for the Treatment of Hepatitis C". Achillion Pharmaceuticals. Retrieved 15 November 2015.
↑ Odalasvir at ChemIDplus
↑ Walker, Tracey (December 2015). "Watch list 2016: top therapeutic areas: experts say you should follow these 6 therapeutic areas.". Managed Healthcare Executive: 47. Retrieved March 12, 2016.
↑ Nakamoto S, Kanda T, Wu S, Shirasawa H, Yokosuka O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J Gastroenterol. 2014 Mar 21;20(11):2902-12. doi: 10.3748/wjg.v20.i11.2902. PMID 24659881
↑ ACH-3102 resources. Achillion pharmaceuticals. Winter 2011. Accessed May 2012.
↑ Achillion gets FDA incentives for hepatitis C drug. Associated Press. 15 May 2012.
↑ Levin, Jules. Preclinical characteristics of ACH-3102. Conference report. European Association for the Study of the Liver, 47th Annual Meeting. April 18th - 22nd 2012. Barcelona, Spain

NS3/4A protease inhibitors (–previr)	Asunaprevir Boceprevir Faldaprevir^‡ Grazoprevir Paritaprevir Simeprevir Telaprevir

NS5A inhibitors (–asvir)	Daclatasvir Elbasvir Ledipasvir MK-3682 MK-8408 Odalasvir^† Ombitasvir Ravidasvir^† Samatasvir^† Velpatasvir

NS5B RNA polymerase inhibitors (–buvir)	Beclabuvir^† Dasabuvir Deleobuvir^§ Filibuvir^§ Setrobuvir^§ Sofosbuvir Radalbuvir^†

Combination drugs	Elbasvir/grazoprevir Ledipasvir/sofosbuvir Ombitasvir/paritaprevir/ritonavir Sofosbuvir/daclatasvir Velpatasvir/sofosbuvir

Anti-influenza agents

Multiple/general

Interferon	Interferon alfa 2b Peginterferon alfa-2a^#

Multiple/unknown	BCX4430^† Favipiravir GS-5734^† Mericitabine^† MK-608^§ NITD008^§ Moroxydine Ribavirin^#/Taribavirin^† Triazavirin

This article is issued from Wikipedia - version of the 11/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.